Mosaic ImmunoEngineering (CPMV) Gains from Investment Securities (2012 - 2016)
Mosaic ImmunoEngineering (CPMV) posted quarterly Gains from Investment Securities of $883600.0 for Q4 2016, up 2003.81% year-over-year from $42000.0 in Q4 2015, and up 2003.81% quarter-over-quarter from $42000.0 in Q4 2015.
Mosaic ImmunoEngineering (CPMV) Gains from Investment Securities (2012 - 2016) Analysis & Trends
Mosaic ImmunoEngineering's Gains from Investment Securities history runs 5 years deep, the most recent figure standing at $883600.0 for Q4 2016.
- In Q4 2016, Gains from Investment Securities rose 2003.81% year-over-year to $883600.0; the TTM figure through May 2017 stood at $883600.0 (up 1423.45% YoY), while the FY2017 annual figure was $883600.0, up 1423.45% from the prior year.
- Gains from Investment Securities for Q4 2016 stood at $883600.0, up from $42000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $883600.0 in Q4 2016, with the low at $800.0 in Q4 2014.
- The 5-year median for Gains from Investment Securities is $213175.0 (2013), against an average of $340280.8.
- The sharpest annual moves came in 2014 and 2015: Gains from Investment Securities sank 99.78% in 2014, then soared 5150.0% in 2015.
- Mosaic ImmunoEngineering's Gains from Investment Securities stood at $625000.0 in 2012, then slumped by 41.0% to $368750.0 in 2013, then tumbled by 99.78% to $800.0 in 2014, then jumped by 5150.0% to $42000.0 in 2015, then surged by 2003.81% to $883600.0 in 2016.
- Business Quant data shows CPMV's Gains from Investment Securities at $883600.0 in Q4 2016, $42000.0 in Q4 2015, and $16000.0 in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2016 | 883,600.00 |
| Nov 30, 2016 | 883,600.00 |
| Nov 30, 2015 | 42,000.00 |
| Nov 30, 2015 | 42,000.00 |
| Aug 31, 2015 | 16,000.00 |
| Aug 31, 2015 | 16,000.00 |
| Feb 28, 2015 | 57,600.00 |
| Feb 28, 2015 | 57,600.00 |
| Nov 30, 2014 | 800.00 |
| Nov 30, 2014 | 800.00 |
| Nov 30, 2013 | 368,750.00 |
| Nov 30, 2013 | 368,750.00 |
| Aug 31, 2013 | 6,250.00 |
| Aug 31, 2013 | 6,250.00 |
| May 31, 2013 | 877,808.00 |
| May 31, 2013 | 877,808.00 |
| Feb 28, 2013 | 525,000.00 |
| Feb 28, 2013 | 525,000.00 |
| Nov 30, 2012 | 625,000.00 |
| Nov 30, 2012 | 625,000.00 |